A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
TRIUMPH-9
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
2 other identifiers
interventional
600
3 countries
35
Brief Summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 obesity
Started Jan 2026
Typical duration for phase_3 obesity
35 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2026
CompletedFirst Posted
Study publicly available on registry
January 22, 2026
CompletedStudy Start
First participant enrolled
January 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2028
April 20, 2026
April 1, 2026
2.7 years
January 16, 2026
April 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent Change from Baseline in Body Weight
Baseline, Week 104
Secondary Outcomes (7)
Change from Baseline in Waist Circumference
Baseline, Week 104
Percent Change from Baseline in Triglycerides
Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Baseline, Week 104
Percent Change from Baseline in High Sensitivity C-Reactive Protein
Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score
Baseline, Week 104
- +2 more secondary outcomes
Study Arms (3)
Retatrutide Dose Escalation 1
EXPERIMENTALParticipants will receive retatrutide subcutaneously (SC)
Retatrutide Dose Escalation 2
EXPERIMENTALParticipants will receive retatrutide SC
Retatrutide Dose Escalation 3
EXPERIMENTALParticipants will receive retatrutide SC
Interventions
Administered SC
Eligibility Criteria
You may qualify if:
- Have a Body Mass Index (BMI) at screening
- ≥ 30 kilogram per square meter (kg/m2) OR
- ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
- Have at least one unsuccessful attempt to lose weight by dieting
You may not qualify if:
- Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
- Have a prior or planned surgical treatment for obesity
- Have type 1 diabetes or type 2 diabetes
- Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Have had within the past 90 days before screening:
- heart attack
- stroke
- hospitalization for unstable angina or heart failure
- Have New York Heart Association Functional Classification Class IV congestive heart failure
- Have a history of chronic or acute pancreatitis
- Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (35)
Arizona Research Center
Phoenix, Arizona, 85053, United States
Care Access - Huntington Beach
Huntington Beach, California, 92648, United States
Los Angeles Institute for Metabolic Research
Los Angeles, California, 90015, United States
New Horizon Research Center
Miami, Florida, 33165, United States
Encore Medical Research - Weston
Weston, Florida, 33331, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, 96817, United States
L-MARC Research Center
Louisville, Kentucky, 40213, United States
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, 02115, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706, United States
NYC Research INC
Long Island City, New York, 11106, United States
Weill Cornell Medical College
New York, New York, 10021, United States
Care Access - Raleigh
Raleigh, North Carolina, 27607, United States
New Phase Research and Development
Knoxville, Tennessee, 37909, United States
Velocity Clinical Research, Dallas
Dallas, Texas, 75230, United States
Cedar Health Research - Texas Native Health
Dallas, Texas, 75235, United States
Cedar Health Research
Dallas, Texas, 75251, United States
Cedar Health Research - Fort Worth
Fort Worth, Texas, 76132, United States
Advanced Research Institute
Ogden, Utah, 84405, United States
Dominion Medical Associates, Inc.
Richmond, Virginia, 23219, United States
CAMC Institute for Academic Medicine
Charleston, West Virginia, 25304, United States
Cicemo Srl
Buenos Aires, 1424, Argentina
CARDIAMET Investigaciones Médicas
Buenos Aires, C1014ACP, Argentina
Stat Research S.A.
Buenos Aires, C1023AAB, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI, Argentina
Centro Médico Viamonte
Buenos Aires, C1120AAC, Argentina
Aggarwal and Associates Limited
Brampton, L6T 0G1, Canada
Med Trust Research
Courtice, L1E 2J5, Canada
Winterberry Research Inc.
Hamilton, L8J 0B6, Canada
Diex Recherche Inc. Division Joliette
Joliette, J6E 6A9, Canada
Milestone Research Inc.
London, N5W 6A2, Canada
Diex Recherche Inc. Division Quebec
Québec, G1V 4T3, Canada
Diex Recherche Inc. Division Sherbrooke
Sherbrooke, J1L 0H8, Canada
Canadian Phase Onward
Toronto, M3J 0K2, Canada
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, M9V 4B4, Canada
C.I.C. Mauricie inc.
Trois-Rivières, G8T 7A1, Canada
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Central Study Contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2026
First Posted
January 22, 2026
Study Start
January 24, 2026
Primary Completion (Estimated)
October 1, 2028
Study Completion (Estimated)
November 1, 2028
Last Updated
April 20, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
- Access Criteria
- A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.